MedTrace Logo

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

NCT00057382 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2005-06-24

No results posted yet for this study

Summary

This is an international, multicenter, randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma (liver cancer). Patients can not have been treated before with chemotherapy and surgery is not recommended for their cancer. A total of 750 subjects will be enrolled in this study.

Conditions

Interventions

DRUG

T138067 intravenous

DRUG

doxorubicin intravenous

Sponsors & Collaborators

  • Tularik

    lead INDUSTRY

Principal Investigators

  • Mohammad Hirmand, MD · Tularik

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31

Countries

  • United States
  • Brazil
  • China
  • Poland
  • Puerto Rico
  • Russia
  • Singapore
  • South Africa
  • Thailand
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00057382 on ClinicalTrials.gov